



Venture Capital Resources . . .

In the past decade we have collaborated with over 200 company clients facilitating growth solutions for the innovation, commercialization, and globalization of technology. We focus on accurate analysis, forecasting, and strategic relationships to provide resilient solutions for our clients who seek stability, growth, and longevity in an ever changing global economy. We facilitate businesses with the infrastructure for profit making growth strategies and solutions through the following services:

Strategic Growth Analysis
Interim Management
Turn-Around / Revitalization

Marketing Evaluation
M&A Planning
Operation Strategies

Collaborative Alliances
Executive Coaching
Venture Capital Leveraging



GSP's extensive long-term relationships with skilled professionals, specialist, thought leaders, academic researchers, and investors offer a collaborative approach to solutions for client companies. Executives in diverse industries recognize GSP's instinct for professional, social, and business intelligence; GSP is in demand for accurate analysis, forecasting, and strategic relationships.

GSP has relationships with many fine institutional lenders and investors that provide capitalization for growth resulting in further R&D, increasing market share and revenue, and accelerating ROI. The following are *'just a sampling'* of the venture capital resources to leverage for our clients:

[Accuitive Medical Ventures](#) is a \$160 million fund that invests exclusively in early stage medical device technology opportunities nationwide.

[Adams Capital Management](#) fund for software-based diagnostic equipment.

[Advanced Technology Ventures](#) focuses on diagnostics manufacturers, minimally invasive surgical instruments, and intracoronary radiation systems.

[Advent International](#) invests in all stages of development for cardiovascular, orthopedic, imaging, and diagnostics providing up to \$200 million in equity for a single transaction. Investment structures vary: minority equity positions, leveraged recapitalizations, and management buyouts. Current portfolio includes companies in the

Contact us by email at: growtholutionsprovider@gmail.com

"Any enterprise is built by wise planning, becomes strong through common sense, and profits wonderfully by keeping abreast of the facts."

[Alliance Technology Ventures](#) invest between \$500,000 and \$2 million in early-stage cardiovascular technologies, surgical devices, and organ repair.

[Alpha Capital Partners](#) provides equity financing for promising growth businesses and buyouts or recapitalizations of established companies. Investment ranges from \$500,000 to \$4 million for automated immunoassay instruments, digital interconnect systems for medical imaging equipment, and surgical cable and instruments.

[Alta Partners](#) prefers to act as the lead investor, taking a board seat, and assisting the company as it develops. Typically, between \$2 million and \$8 million is invested in west coast a companies.

[Ampersand Ventures](#) investments include companies developing microfluidics systems for genetic analysis, automated cancer diagnosis, and reagents and electrophoresis systems for research applications.

[Anthem Capital](#) is a \$43 million fund investing in microprocessor-controlled CPR vest, products for cancer screening, a miniature optical sensor with applications in glucose and oxygen sensing, and products for diagnosing and treating chronic pain.

[ARCH Venture Partners](#) invests in biotech and biopharmaceuticals, optoelectronic implants, therapeutic ultrasound systems, and mammography peripherals.

[Asset Management Associates](#) investments of \$2 - 3 million in early stage diagnostics manufacturers

[Atlas Venture's](#) investment is usually between \$500,000 and \$5 million in genomics and biopharm, cardiac-mapping systems, disposables, diagnostic endoscopes, surgical instruments, medical lasers, and separation products.

The [Aurora Funds](#) are invested primarily in manufacturers of 3-D imaging systems and diagnostic instruments. Investments range from \$250,000 to \$1,500,000. The portfolio lists

[Bancorp Piper Jaffray Ventures](#) Approximately \$80 million under management, focused on medical device for cardiovascular surgery, interventional neuroradiology, minimally invasive orthopedics, urology/women's health/oncology, and tissue engineering/biological.

[Bessemer Venture Partners](#) invests \$1 million and \$5 million in private companies at any stage investments includes MRI and diagnostics companies.

[BioAsia Investments](#) investments from \$0.5 million and \$5 million in companies developing clinical diagnostic reagents and enzyme-based immunoassays, a portable device for measuring blood glucose and glycated protein, and blood processing and cryopreservation equipment.

[Brentwood Venture Capital](#) invests in cardiac, surgical, and imaging companies that will produce greater than \$50 million revenue within five years.

Contact us by email at: growtholutionsprovider@gmail.com

[Canaan Partners](#) investments include makers of hemodialysis equipment, patient monitors, infusion pumps, and orthopedic products. Funds ranging from \$0.5 million to \$15 million for development, expansion stage, management-led buyouts, and recapitalizations..

[Capital Southwest](#) investments include a manufacturer of surgical masks, disposable products, medical x-ray imaging, radiography systems, hematology and blood-chemistry analyzers. Fund provides capital for early-stage, expansion, management buyouts, recapitalizations, and industry consolidations.

[Capstone Ventures](#) invests in early-stage healthcare information technology companies in the West or Upper Midwest. Typically the initial vestment is \$500,000 to \$1,500,000.

[Cardinal Health Partners](#) A \$62 million fund, investing \$2 to \$5 million in each venture. They invest in medical devices, healthcare information systems, healthcare services, and life science technologies.

[Charter Venture Capital](#) \$1 to \$5 Million lead investor contributing resources and management support to manufacturers of controlled-release delivery systems, diagnostics, electrophysiology devices, orthopedics, cancer therapeutics, computer-aided surgical systems, infusion pumps, and hearing aids.

[Clarus Ventures](#) is a life sciences venture capital firm with core expertise in investing in biopharmaceuticals, specialty pharma and medical technology. A management team approach creating value with extensive thought leaders and decision maker relationships at a global level and overseeing R&D, commercialization, business development and operations.

[Collinson Howe & Lennox](#) invests in the areas of women's health, minimally invasive surgery, drug-delivery catheters, treatment of in-stent restenosis; investments range in size from \$100,000 to \$5 million.

[Crosslink Capital](#) invests in biotech, equipment, and medical software firms there are emerging-growth companies with proof-of-concept.

[Crosspoint Venture Partners](#) is an early-stage western state investor interested in equity participation of 20% or more with liquidity in 3 to 7 to seven years. Investments includes manufacturers of blood-pressure monitors, ultrasound contrast agents, and devices to treat neurovascular disorders.

[Domain Associates](#) provides \$30 million to \$40 million annually to medical device firms, including: developers of tumor-ablation devices, wearable defibrillators, minimally invasive surgical instruments, and surgical vision systems.

[Edison Venture Fund](#) \$5 - 20 million revenue private equity and value-added services to information technology businesses throughout the DC corridor.

[Eno River Capital](#) invests in new biotechnology and bioscience companies in North Carolina, managing the North Carolina Bioscience Investment Fund.

Contact us by email at: growtholutionsprovider@gmail.com

[Enterprise Partners](#) invests in privately held early-stage and emerging-growth companies, particularly in the area Southern California's medtech and healthcare services including: manufacturers of OBGYN instruments, cytometers, medical-records software, minimally invasive devices for orthopedics, patient monitors, and noninvasive blood-pressure monitors.

[Finistere Partners LLC](#) \$0.5m to \$5.0m San Diego venture fund focusing on early stage investments in medical devices including: cardiovascular, orthopaedic, and drug delivery systems.

[Fluke Venture Partners](#) minority equity position/investments of \$500,000 and \$2 million in Pacific Northwest companies, maintain a close yet hands-off relationship. Investments include manufacturers of wound-care products, medical lasers, software, coffee, and microbrewers.

[Forward Ventures](#) \$500,000 to \$1,500,000 early-stage biotechnology and healthcare ventures on the West Coast. They have seeded/founded fourteen life-science and healthcare companies in past 7 to 10 years.

[Golden Pine Ventures](#) invest in discovering and developing exceedingly rare early-stage technologies which seed biotechnology and biomedical companies. They have raised over a billion dollars for over two dozen biotechnology and biomedical companies, and have taken seven public.

[Greylock](#), invests in all stages of medical companies including: manufacturers of dialysis equipment, disposables, filtration equipment, orthopedic devices, monitoring equipment, diagnostic, CO₂ analyzers, hospital information systems, neurological therapeutics, and others.

[Hambrecht & Quist Capital Management](#) HQCM focuses on later-stage and mezzanine financings, with initial investments in the \$2 million – \$5 million range in smaller, emerging biotechnology, pharmaceuticals, and medical devices and services companies.

[Hickory Venture Capital](#) invest \$1 million to \$6 million overtime in well managed small but rapidly growing private companies throughout the Southeast, Southwest, Mid-Atlantic, and Midwest.

[Highland Capital Partners](#) invest in manufacturers of anesthesia monitors, DNA-based cancer screening, minimally invasive urological surgical instruments, stents, urology products, and healthcare information systems and technology.

[IVP-Institutional Venture Partners](#) invests \$50,000 to \$4 million in seed or early-stage manufacturers of POC clinical chemistry analyzers, blood-glucose monitoring, revascularization devices, stents, therapeutic ultrasound devices, cytology equipment, and infusion pumps.

[InnoCal](#) focuses is on early- and expansion-stage California companies with IP in orthopedic implants, infusion devices, and urology products.

Contact us by email at: growtholutionsprovider@gmail.com

"Any enterprise is built by wise planning, becomes strong through common sense, and profits wonderfully by keeping abreast of the facts."

[Intersouth Partners](#) lead investor in Southeast technologies including: POC diagnostics, implantables, laparoscopic instruments, and drug-delivery systems. Focus is on seed and early-stage with sales potential exceeding \$20 million in 3–6 years.

[InterWest Partners](#) invest in \$5 million over the life span of a company. An extensive healthcare portfolio including ultrasound imaging, orthopedic surgery, DNA probes, and vascular intervention.

[JP Morgan Partners](#) is the venture branch of J.P. Morgan Chase Bank investing in manufacturers of cardiac catheters, diagnostic systems, orthopedics, liver-assist devices, urological surgery products, blood-glucose monitors, external defibrillators, IV components, and plastic components.

[KBL Healthcare Ventures](#) is a physician-run VC firm focused on noninvasive cardiac diagnostics, women's health, cytology, and healthcare software.

[Kleiner Perkins Caufield & Byers](#) focus on internet technologies, medical device manufacturers orthopedics and neurology.

[Kline Hawkes & Co.](#) investments range from \$3 million to \$6 million for later-stage venture deals, changes of control, and industry consolidations.

[Magic Venture Capital](#) first-round funding for healthcare ventures and medical devices playing key roles in early management.

[Mayfield Fund](#) \$1 billion of capital under management and has invested in more than 300 information technology and healthcare companies since its founding in 1969. The portfolio includes computer-assisted surgery, hearing aids, cardiovascular intervention, and anesthesia monitoring.

[Medicus Venture Partners](#) invests in western US early-stage biotechnology, diagnostics, urology, neuroradiology, ultrasound contrast agents.

[MedVenture Associates](#) early-stage financing of Western region companies in the medical devices, medical information technology, and pharmaceutical and biotechnology products encompasses the cardiovascular, neurovascular, orthopedic, women's health, and instruments equipment.

[Menlo Ventures](#) invests from \$4 million to \$10 million in several rounds of financing in minimally invasive surgical technologies and serves on the boards of over 80% of portfolio companies.

[Mitsui USA Private Equity Group](#) The group's Orien Fund prefers opportunities where pre-money valuations are less than \$20 million in manufacturers of an implantable nerve stimulator, an infusion pump, and a blood-handling device, information technology and healthcare.

Contact us by email at: growtholutionsprovider@gmail.com

"Any enterprise is built by wise planning, becomes strong through common sense, and profits wonderfully by keeping abreast of the facts."

[Morgan Stanley Dean Witter Venture Partners](#) invests in later-stage high-growth companies in the IT and healthcare industries including: cardiology diagnostics, automated sample preparation, and computerized diagnostics.

[Morgenthaler Venture Partners](#) investment ranges from \$2 million to 8 million in VC opportunities and \$5 million to 30 million in management buyouts for medical devices, healthcare services, healthcare information services, and biopharmaceuticals that are early-stage investments or management-led buyouts, build-ups, and recapitalizations.

[MPM Capital](#) is the manager for the \$230 million BioVentures family of venture capital funds that are invested in parallel in selected private healthcare companies in the US and Europe. BB Bioventures LP investments range from \$5 million to \$20 million and includes manufacturers of surgical sealants, diabetes management systems, hearing aids, and transdermal drug-delivery systems.

[New Enterprise Associates](#) initial funding of \$500,000 to \$6 million for ultrasound imaging, endovascular surgery, orthopedics, urology, patient monitoring, cardiology, and life science technologies.

[Newbury Ventures](#) early-stage financing for communication and technology, healthcare, cardiac, surgical instruments.

[Norwest Venture Capital](#) \$1.5 million to \$20 million funds for automated sample preparation, blood-gas sensing, minimally invasive surgery, and orthopedics.

[Olympic Venture Partners](#) \$1 to \$3 million focusing on companies in the Pacific Northwest for manufacturers of cardiology catheters and vascular devices and internet companies.

[Onset Ventures](#) \$1 million to \$4 million seed and early-stage investing for 1st and 2nd round in revascularization, molecular diagnostics, spinal implants, and reproductive health.

[A. M. Pappas & Associates](#) TechAMP's invest into mid-stage companies developing therapeutics, diagnostics, discovery platforms, biotech toolkits, drug-delivery technologies, clinical instrumentation, interventional devices, and regulatory enhancing technologies in Research Triangle Park, NC.

[Partech](#) assists companies at all stages of growth—from the early-stage start-up phase to pre-IPO and beyond. Portfolio companies include device firms active in the cardiology and urology markets as well as manufacturers of surgical sealants and drug-delivery polymers.

[Patricof & Co. Ventures](#) investment ranges \$5 million to \$25 million, takes a lead investor or sole investor position for early-stage, recapitalizations, and off-balance-sheet financing.

[Primus Venture Partners](#) investment size is \$5 million to \$10 million specializes in healthcare services, healthcare information systems, and medical devices including companies involved in diagnostics, sterilization systems, blood processing, and motor-function restoration.

Contact us by email at: growthsolutionsprovider@gmail.com

"Any enterprise is built by wise planning, becomes strong through common sense, and profits wonderfully by keeping abreast of the facts."

[Prism Venture Partners](#) \$50 million to \$100 million focuses on medical devices disposables, healthcare services, healthcare information systems, software, and services.

[River Cities Capital Funds](#) provide growth equity in manufacturer of specialty disposables and a manufacturer of intraoperative surgical navigation systems primarily in the Midwest and Southeast.

[River Delta Ventures](#) \$50,000 to \$500,000 makes seed and first-round investments in California cardiac testing to IVUS imaging companies developing medical devices, healthcare information technology, and healthcare services. Geographical preference is for California.

[RiverVest Venture Partners](#) St. Louis-based firm focuses on early-stage life sciences investments scientists striving to develop breakthrough solutions to unmet clinical needs.

[Ryan Enterprises Group](#) family-owned firm with a capital base of about \$1 billion investing in contract or outsource manufacturers of medical devices posting sales of about \$25 million to \$250 million.

[Seaflower Associates](#) investments range from \$250,000 to \$1,250,000. makes seed and first-round investments in developing biotechnology, medical devices, computer-enhanced laparoscopy to biomaterials to endoscopic imaging, healthcare information technology, and healthcare services in New England and the Great Lakes region.

[Sequoia Capital](#) \$50,000 seed investment to \$10 million transactions in early-stage investments in technology-driven companies on the West Coast. A lengthy device portfolio including: manufacturers of ultrasound equipment, minimally invasive cardiac surgery systems, patient-side diagnostic devices, orthopedic implants, glucose monitors, and BPH treatment systems.

[Sierra Ventures](#) typically likes to serve on the board of directors of portfolio companies managing six venture capital partnerships, which together have more than \$400 million of committed capital. Portfolio including vascular intervention, computer-guided surgery, and diagnostics.

[Sorrento Associates](#) \$25 million to \$50 million in San Diego and Southern California manufacturers of central venous catheters, a solid-state gamma camera, respiratory equipment, infusion pumps, defibrillators, and drug-delivery platforms.

[Spray Venture Partners](#) \$50 million seed and early-stage healthcare venture firm, with a particular focus in medical devices: ultrasound catheters, minimally invasive surgical equipment, microfluidics, AEDs, and drug delivery.

The [Sprout Group](#) \$5 million to \$50 million with a minority interest in diagnostic products covers vascular access, minimally invasive surgery, urology, cardiology, and orthopedics.

[Split Rock Partners](#), formerly part of St. Paul Venture Capital, emerging companies in medical devices and specialty pharmaceuticals and software industries in the Upper Midwest and West Coast.

Contact us by email at: growtholutionsprovider@gmail.com

"Any enterprise is built by wise planning, becomes strong through common sense, and profits wonderfully by keeping abreast of the facts."

[St. Paul Venture Capital](#) \$1 million to \$10 million with a dozen device firms including manufacturers of blood-handling products, x-ray systems, cardiovascular stents, diagnostics, and spinal implants.

[Telegraph Hill Partners](#) \$5M to \$25M in growth-stage companies; focused on chemical and reagent companies, orthopedic and cardiovascular device companies, and medical diagnostic companies.

[TGap Venture Capital Fund](#) \$20 million Michigan fund for early stage medical device, medical services, and IT technology companies. TGap's typical initial investment in a company is between \$250,000 and \$1 Million.

[TL Ventures](#) invests between \$3 million and \$10 million in biopharmaceuticals, manufacturers of diagnostics, and monitoring equipment companies in the early to middle stages of development.

[Tredgar Investments](#) mezzanine financing of \$500,000 to \$4 million for 3-D medical imaging, microfluidics, cryotherapy, coronary revascularization, devices for treating ischemic strokes, surgical instruments, disposable hearing aids, and vascular-access closure systems.

[TVM Techno Venture Management](#) \$100,000 in seed financing to \$3 million to \$5 million in device manufacturers in urology, orthopedics, and imaging; international firm with offices in Munich and Boston.

[U.S. Venture Partners](#) invests in Western US. Healthcare companies developing medical devices including: diagnostic imaging, fluoroscopy, cardiovascular surgery, implantable devices, and drug delivery.

[Vanguard Venture Partners](#) seed and early-stage investments in life sciences, medical devices, diagnostics, biotech instruments, and medical information technology with 10x ROI through acquisition or IPO within 5 to 7 years.

[Venrock Associates](#) venture capital arm of the Rockefeller family; in medical device the focus is on minimally invasive technologies in cardiovascular medicine and orthopedics.

[Venture Investors Management LLC](#) lead investor in seed and early-stage companies in biotechnology, instrumentation, and devices including manufacturers of cardiac analyzers and biodegradable polymers.

[Versant Ventures](#) \$1 billion in committed capital, in its third fund managing 65 companies including the following medical device companies: Acclarent, Calypso Medical Technologies, Cameron Health, LipoSonix, NeoVista, Second Sight, and Spiration.

[Wakefield Group](#) invests \$1 million to \$5 million in mid-Atlantic and Carolinas medical technology companies.

Contact us by email at: growtholutionsprovider@gmail.com

"Any enterprise is built by wise planning, becomes strong through common sense, and profits wonderfully by keeping abreast of the facts."

[Welsh, Carson, Anderson & Stowe](#) focuses on funding healthcare and information service companies with revenues typically between \$30 million and \$200 million.

[Western Technology Investment](#) looks for companies with the potential to generate \$25 million in annual sales within 5 years. Investments range from \$500,000 to \$10 million. Portfolio includes companies active in the cardiovascular, drug delivery, glucose monitoring, and urology markets.

[WFD Ventures LLC](#) typically invests between \$2 million and \$15 million in equity financing to medical device and healthcare technology, therapeutic, diagnostic or drug delivery technologies. They look for strong intellectual property rights and exceptional market potentials. WFD helps its portfolio companies develop liquidity strategies and orchestrate liquidity events. They have built collaborative relationships with all of the major medical device consolidators.

[J.H. Whitney & Co.](#) Fifty-year old fund for manufacturers of minimally invasive devices and separation technology.

[Windward Ventures](#) \$250,000 to \$2 million lead investment for early-stage Southern California companies in interventional cardiology and infusion therapy.

[Zero Stage Capital](#) invests in start-up, early-stage, and on-going Northeast ventures including: cardiac monitoring, Alzheimer's disease testing, waterjet-based surgery, and blood screening.

Contact us by email at: growtholutionsprovider@gmail.com

"Any enterprise is built by wise planning, becomes strong through common sense, and profits wonderfully by keeping abreast of the facts."